检索结果-南通市图书馆

CEPC Technical Design Report

在线全文

学校读者我要写书评

暂无评论

Radiation Detection Technology and Methods 2024年第1期8卷 I0003-I0016,1-1091页

作者： Waleed Abdallah Tiago Carlos Adorno de Freitas Konstantin Afanaciev Shakeel Ahmad Ijaz Ahmed Xiaocong Ai Abid Aleem Wolfgang Altmannshofer Fabio Alves Weiming An Rui An Daniele Paolo Anderle Stefan Antusch Yasuo Arai Andrej Arbuzov Abdesslam Arhrib Mustafa Ashry Sha Bai Yu Bai Yang Bai Vipul Bairathi Csaba Balazs Philip Bambade Yong Ban Tripamo Bandyopadhyay Shou-Shan Bao Desmond P.Barber Ayse Bat Varvara Batozskaya Subash Chandra Behera Alexander Belyaev Michele Bertucci Xiao-jun Bi Yuanjie Bi Tianjian Bian Fabrizio Bianchi Thomas Biekotter Michela Biglietti Shalva Bilanishvili Deng Binglin Denis Bodrov Anton Bogomyagkov Serge Bondarenko Stewart Boogert Maarten Boonekamp Marcello Borri Angelo Bosotti Vincent Boudry Mohammed Boukidi Igor Boyko Ivanka Bozovic Giuseppe Bozzi Jean-Claude Brient Anastasiia Budzinskaya Masroor Bukhari Vladimir Bytev Giacomo Cacciapaglia Hua Cai Wenyong Cai Wujun Cai Yijian Cai Yizhou Cai Yuchen Cai Haiying Cai Huacheng Cai Lorenzo Calibbi junsong Cang Guofu Cao Jianshe Cao Antoine Chance Xuejun Chang Yue Chang Zhe Chang Xinyuan Chang Wei Chao Auttakit Chatrabhuti Yimin Che Yuzhi Che Bin Chen Danping Chen Fuqing Chen Fusan Chen Gang Chen Guoming Chen Hua-Xing Chen Huirun Chen Jinhui Chen Ji-Yuan Chen Kai Chen Mali Chen mingjun Chen mingshui Chen Ning Chen Shanhong Chen Shanzhen Chen Shao-Long Chen Shaomin Chen Shiqiang Chen Tianlu Chen Wei Chen Xiang Chen Xiaoyu Chen Xin Chen Xun Chen Xurong Chen Ye Chen Ying Chen Yukai Chen Zelin Chen Zilin Chen Gang Chen Boping Chen Chunhui Chen Hok Chuen Cheng Huajie Cheng Shan Cheng Tongguang Cheng Yunlong Chi Pietro Chimenti Wen Han Chiu Guk Cho ming-Chung Chu Xiaotong Chu Ziliang Chu Guglielmo Coloretti Andreas Crivellin Hanhua Cui Xiaohao Cui Zhaoyuan Cui Brunella D'Anzi Ling-Yun Dai Xinchen Dai Xuwen Dai Antonio De Maria Nicola De Filippis Christophe De La Taille Francesca De Mori Chiara De Sio Elisa Del Core Shuangxue Deng Wei-Tian Deng Zhi Deng Ziyan Deng Bhupal Dev Tang Dewen Biagio Di Micco Ran Ding Siqin Dingl Yadong Ding Haiyi Dong Jianin AGH university of Science and Technology Faculty of Physics and Applied Computer ScienceKrakow Anhui university HefeiAnhui Applied Physics department Federal Urdu University of ArtsScience and TechnologyIslamabad Banaras Hindu university Institute of ScienceVaranasi Bandirma Onyedi Eylul university Bandirma Beihang university Beijing Beijing Computational Science Research Center Beijing Beijing Conveyi LTD Beijing Beijing Glass Research Institute Co. LtdBeijing Beijing Institute of Technology Beijing Beijing Normal university Beijing Brown university ProvidenceRI Budker Institute of Nuclear Physics Novosibirsk Cadi Ayyad university Laboratory of Fundamental and Applied PhysicsPolydisciplinary FacultyMarrakech Cairo university Giza Center for Theory and Computation National Tsing Hua UniversityHsinchu Central china Normal university WuhanHubei Central South university ChangshaHunan Centro de Fisica Teorica de Particulas Universidade Tecnica de LisboaLisboa Chengdu KaitengSifang Digital Radio&TV Equipment Co. LtdChengduSichuan china academy of engineering physics MianyangSichuan china building materials academy Beijing china Center of Advanced Science and Technology Beijing china Institute of Atomic Energy Beijing china Jiliang university HangzhouZhejiang china Nuclear Instrument CO. LTDBeijing china university of Geosciences Beijing china university of Geosciences WuhanHubei china university of Mining and Technology XuzhouJiangsu china West Normal university NanchongSichuan Chongqing university Department of PhysicsChongqing Chulalongkorn university Bangkok City university of Hong Kong Department of PhysicsHong Kong Cockcroft Institute Daresbury Cornell university IthacaNY CPPM(AMU/IPhU&CNRS/INP) Marseille Dalian Minzu university DalianLiaoning Dalian university of Technology Department of PhysicsDalian Deutsches Elektronen-Synchrotron DESY Hamburg Dzhelepov Laboratory of Nuclear Problems of Joint Institute for Nuclear Research(DLNP JINR) Dubna East china university Of Science And Technol

The Circular Electron Positron Collider(CEPC)is a large scientific project initiated and hosted by china,fostered through extensive collaboration with international *** complex comprises four accelerators:a 30 GeV Linac,a 1.1 GeV Damping Ring,a Booster capable of achieving energies up to 180 GeV,and a Collider operating at varying energy modes(Z,W,H,and tt).The Linac and Damping Ring are situated on the surface,while the subterranean Booster and Collider are housed in a 100 km circumference underground tunnel,strategically accommodating future expansion with provisions for a potential Super Proton Proton Collider(SPPC).The CEPC primarily serves as a Higgs *** its baseline design with synchrotron radiation(SR)power of 30 MW per beam,it can achieve a luminosity of 5×10^(34)cm^(-2)s^(-1)per interaction point(IP),resulting in an integrated luminosity of 13 ab^(-1)for two IPs over a decade,producing 2.6 million Higgs *** the SR power to 50 MW per beam expands the CEPC's capability to generate 4.3 million Higgs bosons,facilitating precise measurements of Higgs coupling at sub-percent levels,exceeding the precision expected from the HL-LHC by an order of *** Technical Design Report(TDR)follows the Preliminary Conceptual Design Report(Pre-CDR,2015)and the Conceptual Design Report(CDR,2018),comprehensively detailing the machine's layout,performance metrics,physical design and analysis,technical systems design,R&D and prototyping efforts,and associated civil engineering ***,it includes a cost estimate and a preliminary construction timeline,establishing a framework for forthcoming engineering design phase and site selection *** is anticipated to begin around 2027-2028,pending government approval,with an estimated duration of 8 *** commencement of experiments and data collection could potentially be initiated in the mid-2030s.

关键词： initiated exceeding precise

Safety profile of 0.0015%tafluprost eye drops in china:a post-marketing observational study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

International Journal of Ophthalmology(English edition) 2023年第1期16卷 108-114页

作者： Xue-Li Chen Yan-Jing Fu Bo Qu Ye-Wei wang Xin Tang Yu-Hong wang Guo-Yi Zhou ming-Kai Lin Jing-Yuan Shen Jin Yao Su-Yan Li Miao-Qin Wu Hua-Zong Peng ming-Ying lai Ren-Yi Wu Yi-Nong Zhang Yan Li Xiao-jun Wu ming-Chang Zhang Su-Ping Guo Xing-Huai Sun department of Ophthalmology Eye&ENT Hospital of Fudan UniversityShanghai 200000China department of Ophthalmology Daqing Ophthalmologic HospitalDaqing 163000Heilongjiang ProvinceChina department of Ophthalmology the Fourth Affiliated Hospital of China Medical UniversityShenyang 110000Liaoning ProvinceChina department of Ophthalmology Da Lian He Eye Specialist HospitalDalian 116000Liaoning ProvinceChina department of Ophthalmology Beijing Tongren HospitalBeijing 100000China department of Ophthalmology Xiamen Eye Center of Xiamen UniversityXiamen 361000Fujian ProvinceChina department of Ophthalmology Yueqing People’s HospitalWenzhou 325600Zhejiang ProvinceChina department of Glaucoma Zhongshan Ophthalmic CenterSun Yat-sen UniversityGuangzhou 510000Guangdong ProvinceChina department of Ophthalmology Shengzhou Shen’s Eye HospitalShaoxing 312400Zhejiang ProvinceChina department of Ophthalmology the Affiliated Eye Hospital of Nanjing Medical UniversityNanjing 210000Jiangsu ProvinceChina department of Ophthalmology Xuzhou No.1 Peoples HospitalXuzhou 221000Jiangsu ProvinceChina department of Ophthalmology Zhejiang Provincial People’s HospitalHangzhou 310000Zhejiang ProvinceChina department of Ophthalmology Wuhan Eyegood Ophthalmic HospitalWuhan 430014Hubei ProvinceChina department of Ophthalmology Shenzhen Eye HospitalShenzhen 518001Guangdong ProvinceChina department of Glaucoma Shanghai Heping Eye HospitalShanghai 200000China department of Ophthalmology Wuxi Second People’s HospitalWuxi 214000Jiangsu ProvinceChina department of Ophthalmology First Affiliated Hospital of Kunming Medical UniversityKunming 650000Yunnan ProvinceChina department of Ophthalmology Union Shenzhen Hospital(Nanshan Hospital)Shenzhen 518000Guangdong ProvinceChina department of Ophthalmology Wuhan Union HospitalWuhan 430000Hubei ProvinceChina department of Ophthalmology Shengyang He Eye Specialist HospitalShenyang 110000Liaoning ProvinceChina

AIM:To investigate the treatment pattern and safety of tafluprost for glaucoma and ocular hypertension(OH)in clinical practice in ***:This post-marketing observational study included patients who received tafluprost to lower intraocular pressure(IOP)within 30d between September 2017 and March 2020 in 20 hospitals in *** drug reactions(ADRs)during tafluprost treatment and within 30d after the treatment were ***:A total of 2544 patients were included in this study,of them 58.5%(1488/2544)had primary open angle glaucoma(POAG),21.9%(556/2544)had OH and 19.7%(500/2544)used tafluprost for other *** 359 ADRs occurred in 10.1%(258/2544)patients,and no serious adverse event *** most common ADR was conjunctival hyperemia(128 ADRs in 124 patients,4.9%).Totally 1670 participants(65.6%)combined tafluprost with carbonic anhydrase inhibitors(CAIs;37.1%,620/1670),sympathomimetics(33.5%,559/1670),β-blockers(33.2%,555/1670),other prostaglandin analogs(PGAs;15.6%,260/1670)and other eye drops(15.1%,253/1670).The highest incidence of conjunctival hyperemia was noted in patients who received tafluprost in combination with other PGAs(23 ADRs in 23 patients,8.8%,23/260)and the lowest was in combination with CAIs(16 ADRs in 16 patients,2.6%,16/620).Tafluprost was applied in primary angle-closure glaucoma(41.6%,208/500),after glaucoma surgery(17.8%,89/500)and after non-glaucoma surgery(15.8%,79/500).CONCLUSION:Tafluprost is safe for POAG and OH,and tolerable when combined with other eye drops and under various clinical circumstances.

关键词： tafluprost glaucoma ocular hypertension intraocular pressure adverse drug reactions

Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2020年第6期26卷 657-669页

作者： Zhe-Xuan wang En-Xin wang Wei Bai Dong-Dong Xia Wei Mu Jing Li Qiao-Yi Yang ming Huang Guo-Hui Xu jun-Hui Sun Hai-Liang Li Hui Zhao Jian-Bing Wu Shu-Fa Yang Jia-Ping Li Zi-Xiang Li Chun-Qing Zhang Xiao-Li Zhu Yan-Bo Zheng Qiu-He wang Jing Li Jie Yuan Xiao-Mei Li Jing Niu Zhan-Xin Yin Jie-lai Xia Dai-ming Fan Guo-Hong Han china HCC-TACE Study Group department of Liver Disease and Digestive Interventional Radiology National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive DiseasesFourth Military Medical UniversityXi’an 710032Shaanxi ProvinceChina department of Radiology the Southwest HospitalThird Military Medical UniversityChongqing 400037China department of Hepatobiliary Surgery the Second Affiliated Hospital of Third Military Medical UniversityChongqing 400037China department of Minimally Invasive International Therapy the Third Affiliated Hospital of Kunming UniversityTumor Hospital of Yunnan ProvinceKunming 650000Yunnan ProvinceChina department of Interventional Radiology Tumor Hospital of Sichuan ProvinceChengdu 610000Sichuan ProvinceChina department of Hepatobiliary and Pancreatic Interventional Cancer the First Affiliated HospitalSchool of MedicineZhejiang UniversityHangzhou 310003Zhejiang ProvinceChina department of Interventional Radiology Henan Cancer Hospitalthe Affiliated Cancer Hospital of Zhengzhou UniversityZhengzhou 450008Henan ProvinceChina department of Interventional Radiology the Affiliated Hospital of Nantong UniversityNantong 226001Jiangsu ProvinceChina department of Oncology the Second Affiliated Hospital of Nanchang UniversityNanchang 330000Jiangxi ProvinceChina department of Interventional Radiology the Affiliated Tumor Hospital of Xinjiang Medical UniversityUrumqi 830001Xinjiang Uygur Autonomous RegionChina department of Interventional Radiology the First Affiliated Hospital of Sun Yatsen UniversityGuangzhou 510080Guangdong ProvinceChina department of Interventional Medical Center the Affiliated Hospital of Qingdao UniversityQingdao 266000Shandong ProvinceChina department of Gastroenterology and Hepatology Shandong Province Hospital affiliated to Shandong UniversityJinan 250021Shandong ProvinceChina department of Interventional Radiology The First Affiliated Hospital of Soochow UniversitySuzhou 215006Jiangsu ProvinceChina department of Interventional Radi

BACKGROUND The treatment outcome of transarterial chemoembolization(TACE)in unresectable hepatocellular carcinoma(HCC)varies greatly due to the clinical heterogeneity of the ***,several prognostic systems have been proposed for risk stratification and candidate identification for first TACE and repeated TACE(re-TACE).AIM To investigate the correlations between prognostic systems and radiological response,compare the predictive abilities,and integrate them in sequence for outcome *** This nationwide multicenter retrospective cohort consisted of 1107 unresectable HCC patients in 15 Chinese tertiary hospitals from January 2010 to May *** Hepatoma Arterial-embolization Prognostic(HAP)score system and its modified versions(mHAP,mHAP2 and mHAP3),as well as the six-and-twelve criteria were compared in terms of their correlations with radiological response and overall survival(OS)prediction for first *** same analyses were conducted in 912 patients receiving re-TACE to evaluate the ART(assessment for re-treatment with TACE)and ABCR(alpha-fetoprotein,Barcelona Clinic Liver Cancer,Child-Pugh and Response)systems for post re-TACE survival(PRTS).RESULTS All the prognostic systems were correlated with radiological response achieved by first TACE,and the six-and-twelve criteria exhibited the highest correlation(Spearman R=0.39,P=0.026)and consistency(Kappa=0.14,P=0.019),with optimal performance by area under the receiver operating characteristic curve of 0.71[95%confidence interval(CI):0.68-0.74].With regard to the prediction of OS,the mHAP3 system identified patients with a favorable outcome with the highest concordance(C)-index of 0.60(95%CI:0.57-0.62)and the best area under the receiver operating characteristic curve at any time point during follow-up;whereas,PRTS was well-predicted by the ABCR system with a C-index of 0.61(95%CI:0.59-0.63),rather than ***,combining the mHAP3 and ABCR systems identified candidates suitable for TA

关键词： Transarterial chemoembolization Hepatocellular carcinoma Prognostic system Radiological response Overall survival Predictive ability

Comparison of outcomes after human leukocyte antigen-matched and haploidentical hematopoietic stem-cell transplantation for multiple myeloma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Medical Journal 2019年第15期132卷 1765-1772页

作者： Yao Chen Wei-jun Fu Lan-Ping Xu Han-Yun Ren Yong-Rong lai Dai-Hong Liu Lin Liu Zi-Min Sun Yuan-Bin Wu Xin wang Ling-Hui Xia ming Jiang Tong-Lin Hu Ding-ming Wan Xiao-jun Huang department of Hematology Peking University People's Hospital Peking University Institute of Hematology Beijing Key Laboratory of Hematopoietic Stem Cell TransplantationBeijing 100044 China department of Hematology Wuhan Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei 430022 China Hematologic Disease Center First Affiliated Hospital of Xinjiang Medical UniversityXinjiang Uygur Autonomous Region Research Institute of Hematology Urumqi Xinjiang 830054 China department of Hematology Zhejiang Provincial Hospital of Traditional Chinese Medicine Zhejiang International Exchange Center of Clinical Traditional Chinese Medicine The First Affiliated Hospital of Zhejiang Chinese Medical University Hangzhou Zhejiang 310006 China department of Hematology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan 450052 China Peking-Tsinghua Center for Life Sciences Beijing 100871 China department of Hematology The Myeloma & Lymphoma Center Changzheng Hospital The Second Military Medical University Shanghai 200003 China department of Hematology Peking University First Hospital Beijing 100034 China department of Hematology The First Affiliated Hospital of Guangxi Medical University Nanning Guangxi 530021 China department of Hematology Chinese People's Liberation Army General Hospital Beijing 100853 China department of Hematology The First Affiliated Hospital of Chongqing Medical University Chongqing 400042 China department of Hematology Anhui Provincial Hospital The First Affiliated Hospital of University of Science and Technology of China Hefei Anhui 230001 China department of Hematology Guangdong Provincial Hospital of Chinese Medicine Guangzhou Guangdong 510530 China department of Hematology Shandong Provincial Hospital Jinan Shandong 250021 China

Background:Allogeneic stem-cell transplantation (SCT) is a well-established immunotherapeutic strategy for multiple myeloma (MM) with a potent and often sustained graft-vs.-myeloma *** multicenter investigation aimed to analyze the complications and survival of haploidentical SCT in patients with MM,and compare the main outcomes with matched-related donors (MRDs).Methods:Haploidentical and MRD SCT was identified from a cohort of 97 patients with MM who received a myeloablative transplantation in 13 hospitals from May 2001 to December 2017.A matched-pair analysis was *** each haplo recipient,the recipients were randomly selected from the MRD group and were matched according to the following criteria:year of the hematopoietic SCT (±2 years),disease status at transplantation,and the length of ***:Seventy cases received MRD and 27 received haploidendcal *** two groups showed no significant ifferences regarding age,gender,cytogenetic risk,and diagnostic *** cumulative incidences of non-relapse mortality (NRM) at1 and 3 years based on donor type were 20.5%(95% confidence interval [CI],10.90-30.10%) and 24.2%(95% CI,13.81-34.59%) for the MRD group and 16.80%(95% CI,1.71-31.89%) and 28.70%(95% CI,8.71-48.69%) for the haplo group,*** incidence of NRM did not differ significantly between the two groups (x2 =0.031,P =0.861).The cumulative incidences of progression-free survival (PFS) and 1 year and 3 years by type of donors were 59.8 %(95 % CI,48.24-71.36 %) and 45.4 %(95 % CI,33.44-57.36%),and 65.6%(95% CI,47.18-84.02%) and 26.8%(95% CI,7.59-46.01%) for MRD and haploidentical donor,*** incidence of PFS did not differ significantly between the two groups (x2 =0.182,P =0.670).In multivariate analyses,no statistically significant differences were observed between haploidentical and MRD for relapse,NRM,PFS,and overall *** were no statistically differences on main outcomes after ha

关键词： Allogeneic stem-cell transplantation Multiple myeloma

Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma:A single-arm, multicenter, prospective study

在线全文

学校读者我要写书评

暂无评论

Hepatobiliary & Pancreatic Diseases International 2022年第2期21卷 106-112页

作者： Ren-Yi Su Sun-Bin Ling Qiao-Nan Shan Xu-Yong Wei Rui wang Chang-Ku Jia Li Zhuang Tian Shen Li-Min Ding Zhi-Dan Xu lai-Bang Luo Li-Bo Sun Guang-ming Li Tai-Shi Fang Nan Jiang Kun Zhang Zhao-Jie Su Zhi-Hai Peng Ren Lang Tao Jiang Qiang He Lin-Sen Ye Yang Yang Yu-Ting He Wen-Zhi Guo Liu-Gen Lan Xu-Yong Sun Dong Chen Zhi-Shui Chen Da-Wei Zhou Shao-jun Ye Qi-Fa Ye Min Tian Jian-Hua Shi Bo wang Jiang Liu Qian Lu Wei Rao Jin-Zhen Cai Tao Lv Jia-Yin Yang Pu-Sen wang Lin Zhong Jing-Sheng Ma Qi-Gen Li Sheng-Dong Wu Chang-Jiang Lu Cai-De Lu Dong-Hua Zhang Xuan wang Zi-Qiang Li Mu-Jian Teng jun-Jie Li Wen-Tao Jiang Jian-Hua Li Quan-Bao Zhang Ning-Qi Zhu Zheng-Xin wang Kang He Qiang Xia Shao-Hua Song Zhi-Ren Fu Wei Qiu Guo-Yue Lv Rui-Peng Song Ji-Zhou wang Zheng wang Jian Zhou Gang Chen Ying-Peng Zhao Li Li Ze-Min Hu Qi-Jie Luo Zhong-Zhou Si Bin Xie Xiao-Shun He Zhi-Yong Guo Shu-Sen Zheng Xiao Xu department of Hepatobiliary and Pancreatic Surgery The Center for Integrated Oncology and Precision MedicineAffiliated Hangzhou First People’s HospitalZhejiang University School of MedicineHangzhou 310006China NHC Key Laboratory of Combined Multi-organ Transplantation Hangzhou 310003China department of Hepatobiliary and Pancreatic Surgery Shulan(Hangzhou)HospitalZhejiang Shuren University School of MedicineHangzhou 310022China department of Hepatobiliary and Pancreatic Surgery The First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China department of Transplantation Jiangxi Provincial People’s Hospital Affiliated to Nanchang UniversityNanchang 330006China Liver Transplantation Center Beijing You’an HospitalCapital Medical UniversityBeijing 100069China department of Hepatic Surgery National Clinical Research Center for Infectious DiseaseShenzhen Third People’s HospitalThe Second Affiliated Hospital of Southern University of Science and TechnologyShenzhen 518112China department of General Surgery Xiang’an Hospital of Xiamen UniversityXiamen 361000China Deartment of Hepatobiliary and Pancreaticosplenic Surgery Beijing Chaoyang HospitalCapital Medical UniversityBeijing 100020China department of Hepatic Surgery and Liver Transplantation Center The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510630China department of Hepatobiliary and Pancreatic Surgery The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China department of Liver Transplantation The Second Affiliated Hospital of Guangxi Medical UniversityNanning 530000China Institute of Organ Transplantation Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Institute of Hepatobiliary Diseases of Wuhan university Transplant Center of Wuhan UniversityHubei Key Laboratory of Medical Technology on TransplantationZhongnan Hospital of Wuhan UniversityWuhan 430071China department of Hepatobiliary Surgery The First Affiliated Hos

Mammalian target of rapamycin(m TOR) inhibitor as an attractive drug target with promising antitumor effects has been widely investigated. High quality clinical trial has been conducted in liver transplant(LT) recipients in Western countries. However, the pertinent studies in Eastern world are paucity. Therefore, we designed a clinical trial to test whether sirolimus can improve recurrence-free survival(RFS) in hepatocellular carcinoma(HCC) patients beyond the Milan criteria after LT. This is an open-labeled, single-arm, prospective, multicenter, and real-world study aiming to evaluate the clinical outcomes of early switch to sirolimus-based regimens in HCC patients after LT. Patients with a histologically proven HCC and beyond the Milan criteria will be enrolled. The initial immunosuppressant regimens are center-specifc for the frst 4-6 weeks. The following regimens integrated sirolimus into the regimens as a combination therapy with reduced calcineurin inhibitors based on the condition of patients and centers. The study is planned for 4 years in total with a 2-year enrollment period and a 2-year follow-up. We predict that sirolimus conversion regimen will provide survival benefts for patients particular in the key indicator RFS as well as better quality of life. If the trial is conducted successfully, we will have a continued monitoring over a longer follow-up time to estimate indicator of overall survival. We hope that the outcome will provide better evidence for clinical decision-making and revising treatment guidelines based on Chinese population data.

关键词： Sirolimus Immunosuppressive agents Hepatocellular carcinoma Liver transplantation Conversion

基于网络药理学和分子对接技术探究左卡尼汀治疗附睾炎的作用机制

在线全文

学校读者我要写书评

暂无评论

中华男科学杂志 2023年第8期29卷 698-704页

作者：战明威王磊詹绪新刘朋飞娄强赖雨琪余怡商学军南京大学医学院附属金陵医院/东部战区总医院泌尿外科江苏南京210002 东南大学医学院江苏南京210009 西安市人民医院(西安市第四医院)生殖医学中心陕西西安710004 贵州中医药大学第二附属医院泌尿外科贵州贵阳550001 南京中医药大学江苏南京210022 宁波大学附属第一医院生殖医学中心浙江宁波315000

目的:基于网络药理学及实验研究探究左卡尼汀治疗附睾炎的潜在作用机制。方法:通过多个数据库联用检索出附睾炎与左卡尼汀相关的靶蛋白,在Venny软件获得两者的共同靶点。应用STRING数据库获得蛋白-蛋白之间的相互关系。利用Cytoscape软... 详细信息

目的:基于网络药理学及实验研究探究左卡尼汀治疗附睾炎的潜在作用机制。方法:通过多个数据库联用检索出附睾炎与左卡尼汀相关的靶蛋白,在Venny软件获得两者的共同靶点。应用STRING数据库获得蛋白-蛋白之间的相互关系。利用Cytoscape软件进行可视化,拓扑分析后筛选出关键靶点。使用DAVID数据库进行GO与KEGG通路富集分析。使用Autodock Vina进行分子对接。结果:共获得药物靶点130个,疾病靶点2 151个,共同靶点47个。PPI网络分析得到左卡尼汀治疗附睾炎的核心靶点包括AKT1、HSP90AA1、ALB、CASP3、GSK3B和GSR等。KEGG通路分析提示代谢途径、脂质与动脉粥样硬化、癌症途径、流体剪切应力与动脉粥样硬化、麻疹、化学致癌物质-活性氧物质、嘌呤代谢、P13K-Akt等信号通路可能与左卡尼汀治疗附睾炎的机制有关。结论:本研究通过网络药理学揭示了左卡尼汀可能作用于AKT1、HSP90AA1、ALB、CASP3、GSK3B、GSR等靶点调节多条信号通路,从而可能发挥对附睾炎的治疗效果。

关键词：左卡尼汀附睾炎网络药理学分子对接技术

基于网络药理学探究消瘰丸(Ⅱ)治疗附睾炎的作用机制

在线全文

学校读者我要写书评

暂无评论

中华男科学杂志 2023年第4期29卷 298-305页

作者：战明威娄强刘鹏飞王磊詹绪新赖雨琪余怡商学军南京大学医学院附属金陵医院/东部战区总医院泌尿外科江苏南京210002 贵州中医药大学第二附属医院泌尿外科贵州贵阳550001 东南大学医学院江苏南京210009 西安市人民医院(西安市第四医院)生殖医学中心陕西西安710004 宁波大学附属第一医院生殖医学中心浙江宁波315010

目的:应用网络药理学方法探究消瘰丸(Ⅱ)治疗附睾炎的潜在作用机制。方法:通过多个数据库联用检索出附睾炎与消瘰丸(Ⅱ)相关的靶点,在Venny平台获得两者的共同靶点。应用STRING数据获得蛋白-蛋白之间的相互关系,利用Cytoscape软件进行... 详细信息

目的:应用网络药理学方法探究消瘰丸(Ⅱ)治疗附睾炎的潜在作用机制。方法:通过多个数据库联用检索出附睾炎与消瘰丸(Ⅱ)相关的靶点,在Venny平台获得两者的共同靶点。应用STRING数据获得蛋白-蛋白之间的相互关系,利用Cytoscape软件进行可视化。拓扑分析后筛选出关键靶点。使用DAVID数据库进行GO与KEGG通路富集分析。结果:共获得药物靶点238个,疾病靶点2150个,共同靶点85个。PPI网络分析得到消瘰丸(Ⅱ)治疗附睾炎的核心靶点包括TNF、IL6、IL1B、MMP9、AKT1、PTGS2和TP53等。GO功能分析结果显示共同靶点参与缺氧的反应、细胞凋亡过程的调控、炎症反应、MAPK级联反应的正调控等生物过程。KEGG通路分析提示癌症通路、PI3K-Akt通路、癌症中的蛋白聚糖通路、Ras信号通路及化学致癌–受体激活通路等信号通路可能与消瘰丸(Ⅱ)治疗附睾炎的机制有关。结论:本研究利用网络药理学的方法发现消瘰丸(Ⅱ)治疗附睾炎的潜在靶点和通路,初步探索其作用机制,为后续的研究提供了一些新的思路。

关键词：消瘰丸附睾炎网络药理学

A practical community-based response strategy to interrupt Ebola transmission in sierra Leone, 2014–2015

在线全文

学校读者我要写书评

暂无评论

Infectious Diseases of Poverty 2016年第1期5卷 670-679页

作者： Zhong-Jie Li Wen-Xiao Tu Xiao-Chun wang Guo-Qing Shi Zun-Dong Yin Hai-jun Su Tao Shen Da-Peng Zhang Jian-Dong Li Shan Lv Chun-Li Cao Rui-Qian Xie Hong-Zhou Lu Rong-Meng Jiang Zheng Cao Zhi-Jie An Lei-Lei Li Jie Xu Yan-Wen Xiong Wei Zang Wei Zhang Hong-Wei Zhang Wen-Sen Chen Hua Ling Wen Xu Jian Cai Huan-Jin Luo Xue-Sheng Xing Can-jun Zheng Qiang Wei Xin-Xu Li Mei Li Hai Jiang Li-Quan Deng ming-Quan Chen Xiang Huo Feng Xu Xue-Hui lai Xi-Chen Bai Long-Jie Ye Jian-Yi Yao Wen-Wu Yin Jiao-Jin Sun Lin Xiao Fu-Qiang Liu Xiao-Qiang Liu Hong-Wei Fan Zeng-Qiang Kou Ji-Kun Zhou Hao Zhang Da-Xin Ni Thomas TSamba Qun Li Hong-Jie Yu Yu wang Xiao-Feng Liang Division of Infectious Disease Key Laboratory of Surveillance and Early-warning on Infectious DiseaseChinese Center for Disease Control and PreventionBeijingChina Public Health Emergency Center Chinese Center for Disease Control and PreventionBeijingChina National Center for AIDS/STD Control and Prevention Chinese Center for Disease Control and PreventionBeijingChina Chinese Field Epidemiology Training Program Chinese Center for Disease Control and PreventionBeijingChina National Immunization Program Chinese Center for Disease Control and PreventionBeijingChina Bureau of Disease Prevention and Control National Health and Family Planning Commission of the People’s Republic of ChinaBeijingChina National Institute for Viral Disease Control and Prevention Chinese Center for Disease Control and PreventionBeijingChina National Institute of Parasitic Disease Chinese Center for Disease Control and PreventionShanghaiChina Chinese Center for Health Education BeijingChina department of Infectious Diseases Shanghai Public Health Clinical CenterShanghaiChina Beijing Ditan Hospital Capital Medical UniversityBeijingChina Health News BeijingChina National Institute for Communicable Disease Control and Prevention Chinese Center for Disease Control and PreventionBeijingChina department of Training Chinese Center for Health EducationBeijingChina Center for Infectious Diseases Beijing Youan HospitalCapital Medical UniversityBeijingChina Infection Management The First Affiliated Hospital of Nanjing Medical UniversityNanjingChina Chongqing Municipal Center for Disease Control and Prevention ChongqingChina Yunnan Provincial Center for Disease Control and Prevention KunmingChina Division of Infectious Disease Control and Prevention Zhejiang Provincial Center for Disease Control and PreventionHangzhouChina Guangdong Provincial Center for Disease Control and Prevention GuangzhouChina Division of Acute Infectious Disease Control and Prevention Hubei Provincial Center for Disease Control and PreventionW

Background:The Ebola virus disease spread rapidly in West Africa in 2014,leading to the loss of thousands of *** engagement was one of the key strategies to interrupt Ebola transmission,and practical community level measures needed to be explored in the field and tailored to the specific context of ***:First,community-level education on Ebola virus disease(EVD)prevention was launched for the community’s social mobilizers in six districts in Sierra Leone beginning in November ***,from January to May of 2015,in three pilot communities,local trained community members were organized to engage in implementation of EVD prevention and transmission interruption measures,by involving them in alert case report,contact tracing,and social *** epidemiological indicators of transmission interruption in three study communities were ***:A total of 6016 community social mobilizers from 185 wards were trained by holding 279 workshops in the six districts,and EVD message reached an estimated 631680 *** three pilot communities,72 EVD alert cases were reported,with 70.8%of them detected by trained local community members,and 14 EVD cases were finally *** tracing detected 64.3%of EVD *** median duration of community infectivity for the cases was 1 *** secondary attack rate was 4.2%,and no third generation of infection was *** health worker was infected,and no unsafe burial and noncompliance to EVD control measures were *** community-based measures were modeled to reduce 77 EVD cases,and the EVD-free goal was achieved four months earlier in study communities than whole country of Sierra ***: The community-based strategy of social mobilization and community engagement was effective in casedetection and reducing the extent of Ebola transmission in a country with weak health system. The successfullypractical experience to reduce the risk of Ebola transmission in the

关键词： Ebola virus disease Community engagement Health education Outbreak control

苗药酢浆草组方对慢性非细菌性前列腺炎药物作用机制研究

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中华男科学杂志 2023年第9期29卷 783-789页

作者：赖雨琪余怡刘朋飞战明威马梦飞王磊娄强商学军南京中医药大学金陵临床医学院江苏南京210002 宁波大学附属第一医院生殖医学中心浙江宁波315012 南京大学医学院附属金陵医院/东部战区总医院泌尿外科江苏南京210002 东南大学医学院江苏南京210002

目的:探索苗药酢浆草组方对慢性非细菌性前列腺炎药物作用机制研究。方法:采用1%无菌角叉菜胶溶液刺激诱导建立慢性非细菌性前列腺炎大鼠模型。成模后,将大鼠随机分为两组,对照组(Model组)和酢浆草组(Observation组);另外设置一组假手术... 详细信息

目的:探索苗药酢浆草组方对慢性非细菌性前列腺炎药物作用机制研究。方法:采用1%无菌角叉菜胶溶液刺激诱导建立慢性非细菌性前列腺炎大鼠模型。成模后,将大鼠随机分为两组,对照组(Model组)和酢浆草组(Observation组);另外设置一组假手术组(Sham组),在前列腺左右腹叶注射0.1ml生理盐水。假手术组和对照组大鼠给予0.01 ml/g生理盐水灌胃,酢浆草组大鼠给予酢浆草组方温水煎剂1 ml/100g(1g/kg)灌胃,每日1次,连续灌胃28 d。大鼠末次给药24 h后,腹主动脉取血10 ml,收集大鼠的前列腺组织样本。采用苏木精-伊红染色法(HE)观察正常与前列腺炎大鼠的前列腺形态学结构,ELISA法检测血清和前列腺细胞因子水平,Western印迹法检测4-HNE、ALDH2、FGF2蛋白表达。结果:与正常对照组比较,模型组大鼠前列腺组织间质内纤维组织明显增生,腺体结构紊乱,腺泡内上皮细胞呈乳头状增生,腺泡内可见少量淋巴细胞、单核细胞等炎性细胞浸润,病理评分升高;前列腺组织4-HNE、ALDH2、MCP-1和FGF2蛋白表达显著升高。与模型对照组比较,酢浆草组大鼠前列腺组织轻微损伤,有少量纤维增生和炎性细胞浸润;前列腺组织中4-HNE、ALDH2、MCP-1和FGF-2蛋白表达降低。结论:酢浆草组方可有效改善CNP大鼠前列腺组织病理形态,其作用机制可能与激活4-HNE蛋白,降低大鼠前列腺组织氧化应激损伤有关。

关键词：酢浆草慢性非细菌性前列腺炎纤维化